
Abbott India Analyst Review 2027: A 38.7% ROE, a 2.5% Dividend Yield and Targets Up to ₹36,457. Why Is the Stock Flat?
Updated: 17 Nov 2026 • 10:08 am
Posted by:

Abbott India Stock Snapshot (16 Nov 2026 close)
- Current Market Price (CMP): ₹25,980
- 52-Week High / Low: ₹30,655 / ₹24,650
- Market Capitalisation: ₹55,151 crore
- P/E Ratio vs Industry P/E: 33.4 vs 52.2
- Latest Quarter (Q2 FY27) Revenue: ₹2,019 crore (total income)
- Latest Quarter (Q2 FY27) Net Profit: ₹453 crore
Quick Answer: The Abbott India analyst review 2027 is positive: ICICI Securities has a Buy with a ₹32,210 target and BOB Capital Markets a Buy at ₹36,457. From the 16 November close of ₹25,980, that implies about 24% to 40% upside. Q2 FY27 profit rose 9.2% to ₹453 crore and EBITDA reached ₹568 crore, but revenue growth has been in single to low double digits. The stock trades at a P/E of 33, below the pharma industry's 52, with a dividend yield near 2.5%.
The Abbott India analyst review 2027 features one of the most profitable companies in Indian pharma, and one of the quietest stocks. Anyone tracking the Abbott India share price target 2027 will see brokerage targets well above the market price. Yet the stock, at ₹25,980, sits only 5% above its 52-week low and about 15% below its high.
Abbott India is the listed Indian arm of US healthcare group Abbott, which holds 74.99%. It sells well-known prescription and over-the-counter brands in thyroid, women's health, gastro and diabetes care. Return on equity is a remarkable 38.7%, debt is almost nil, and the dividend yield is about 2.5%. So why is the stock flat?
Click Here – Get Free Investment Predictions
Brokerage Views in the Abbott India Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| BOB Capital Markets | Buy | ₹36,457 | May 2026 |
| ICICI Securities | Buy | ₹32,210 | August 2026 |
ICICI Securities values the company at 36 times its FY28 estimated earnings, arguing that brand stickiness and launch momentum justify the premium. Its August update came after a weak June quarter, when revenue grew only 4.3% against a high base of 12%. BOB Capital Markets set the higher figure in May. Neither report covers the Q2 FY27 results, and we could not verify any later revisions.
The Abbott India analyst review 2027 therefore says the business is fine. The stock's problem is growth speed, not quality.
Q2 FY27 Numbers Behind the Abbott India Analyst Review 2027
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Total Income | ₹2,019 crore | ₹1,889 crore | +6.9% |
| EBITDA | ₹568 crore | Lower | Higher |
| Net Profit | ₹453 crore | ₹415 crore | +9.2% |
Revenue from operations grew 11%, a clear pick-up from the 4.3% seen in the June quarter. Steady demand for domestic branded drugs and cost discipline helped. Profit grew a little slower than sales, but the EBITDA margin stayed close to 28% of total income, among the highest in the industry.
For the first half of FY27, total income stood at ₹3,908 crore and profit at ₹882 crore. That puts the company on track for another year of steady, if unspectacular, earnings growth in the Abbott India analyst review 2027.
Abbott India Business Model Explained
An Abbott India share analysis begins with brands. Doctors prescribe by brand name in India, and patients often stay on the same brand for years. Abbott India owns or markets several category leaders:
- Thyroid: Thyronorm, one of the most prescribed thyroid brands in the country.
- Women's health: Duphaston and related products for pregnancy and gynaecology.
- Gastro: Udiliv, Duphalac, Cremaffin and Digene, which span prescription and over-the-counter sales.
- Diabetes and metabolics: Insulin and other diabetes brands, including products marketed with partners.
The Abbott India analyst review 2027 notes that the company does not run a large research programme in India, and it relies on the parent and partners for new molecules. Its edge is a strong field force and doctor trust. This model needs little capital, which is why ROE is so high and the company pays out most of its earnings.
What Could Drive the Abbott India Analyst Review 2027 Higher
New launches: ICICI Securities flagged launch momentum as a key reason for its premium multiple. New brands in chronic therapies add recurring revenue.
Chronic disease growth: Thyroid, diabetes and gastro conditions are rising with lifestyle changes, and patients stay on treatment for long periods.
Over-the-counter expansion: Brands like Digene and Cremaffin can grow through pharmacies and e-commerce without a prescription.
Steady dividends: A high payout gives a cash return while investors wait for faster growth.
Risks Analysts Flag in the Abbott India Analyst Review 2027
- Generic competition: Lower-priced copies of power brands can cut prices and share.
- Price controls: Drugs on the national essential medicines list face government price caps.
- Slow growth: Revenue growth of 4% to 11% a quarter is modest next to faster-growing peers like Ajanta Pharma.
- Partner dependence: Some products come through tie-ups that can be renegotiated or ended.
- Low liquidity: With a high share price and small free float, the stock can move sharply on small volumes.
Compare Pharma Stocks on the Univest Screener
Key Numbers From the Abbott India Analyst Review 2027
| Parameter | Value |
|---|---|
| Market Cap | ₹55,151 crore |
| P/E (TTM) / Industry P/E | 33.4 / 52.2 |
| Price to Book | 12.9 |
| Return on Equity | 38.7% |
| Debt to Equity | 0.04 |
| Dividend Yield | 2.53% |
| EPS (TTM) | ₹777.82 |
The P/E ratio stands out. At 33.4, Abbott India trades well below the pharma industry average of 52.2, a rare discount for a company with near-zero debt and a 38.7% ROE. Compared with stocks in the Nifty Pharma index, it offers lower growth but higher cash returns.
Who Owns the Stock
| Holder | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|
| Promoter (Abbott group) | 74.99% | 74.99% | 74.99% | 74.99% | 74.99% |
| FIIs | 0.16% | 0.18% | 0.26% | 0.38% | 0.40% |
| DIIs | 9.11% | 9.00% | 8.93% | 8.78% | 8.99% |
| Public | 15.75% | 15.83% | 15.81% | 15.85% | 15.63% |
Ownership is very stable. Foreign holding has risen from a tiny 0.16% to 0.40%, but remains small. Domestic funds, including midcap index funds, hold about 9%. For the Abbott India analyst review 2027, the lack of selling by institutions suggests long-term holders are content with the cash flows.
Upcoming Triggers After the Abbott India Analyst Review 2027
- Q3 FY27 results (around February 2027): Whether revenue growth holds near 11% or slips back.
- New product launches: Additions in chronic and over-the-counter categories.
- Dividend for FY27: Usually announced with full-year results in May.
- Price control changes: Any change to the essential medicines list.
- Fresh targets: Updated broker views after the September quarter.
Bottom Line of the Abbott India Analyst Review 2027
The Abbott India analyst review 2027 shows a cash machine priced at a discount to its industry. ROE of 38.7%, almost no debt and a 2.5% dividend yield are rare in Indian pharma. The Q2 FY27 results also showed revenue growth recovering to 11%.
What holds the stock back is pace. Investors are paying for faster growers elsewhere. The verified targets of ₹32,210 and ₹36,457 assume Abbott India keeps compounding steadily. For the Abbott India stock outlook 2027, a few quarters of double-digit growth would do more for the price than any single launch.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What is the overall reading of the Abbott India analyst review 2027?
The Abbott India analyst review 2027 shows two Buy ratings, from ICICI Securities at ₹32,210 and BOB Capital Markets at ₹36,457. Both value the company's strong brands, high ROE and steady cash flow. The targets imply roughly 24% to 40% upside from ₹25,980. The main concern is that growth has been modest.
What is the Abbott India share price target 2027?
Verified brokerage targets range from ₹32,210 to ₹36,457. ICICI Securities based its August 2026 target on 36 times FY28 estimated earnings. BOB Capital Markets set the higher figure in May 2026. Both were set before the Q2 FY27 results and are third-party opinions.
Which Q2 FY27 numbers anchor the Abbott India analyst review 2027?
Net profit rose 9.2% to ₹453 crore and total income grew 6.9% to ₹2,019 crore. Revenue from operations increased about 11%, a pick-up from 4.3% in the June quarter. EBITDA came in at ₹568 crore. First-half profit reached ₹882 crore.
Why does the Abbott India analyst review 2027 highlight such a high ROE?
The company sells strong brands through a large field force but does not need heavy factories or research spending in India. That keeps capital needs low. Debt is almost nil, and most earnings are paid out as dividends. As a result, return on equity stands at about 38.7%.
Is Abbott India stock expensive?
At a P/E of 33.4, Abbott India trades well below the pharma industry average of 52.2. Its price to book of 12.9 looks high, but that reflects the high ROE. The dividend yield of 2.53% is also generous for a pharma stock. The Abbott India analyst review 2027 sees valuation as reasonable for its quality.
What are the biggest risks in the Abbott India analyst review 2027?
Generic competition against power brands is the main risk. Government price caps on essential drugs can cut realisations. Revenue growth has been slower than many peers. Some products depend on partnerships that could change.
What will decide the Abbott India stock outlook 2027?
The Q3 FY27 results, due around February 2027, will show if revenue growth stays near 11%. New launches in chronic and over-the-counter categories are important. The FY27 dividend, usually announced in May, matters for income investors. Fresh brokerage targets after the September quarter will update the Abbott India analyst review 2027.
Recent Articles

Max Pain Theory Explained: How the Max Pain Strike Is Calculated, How It Is Used Around Expiry and Why It Is Not a Reliable Predictor
17 November 2026

Synthetic Long and Short Explained: How Options Mimic Futures, Payoff, Margin, Costs and Why Traders Use Them
17 November 2026

Diagonal Spread Explained: How Different Strikes and Different Expiries Are Combined, Payoff, Risks and How It Differs From a Calendar Spread
17 November 2026

Iron Butterfly Explained: How the Four Leg Options Strategy Is Built, Maximum Profit and Loss, Break-Even Points and How It Differs From an Iron Condor
17 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Max Pain Theory Explained: How the Max Pain Strike Is Calculated, How It Is Used Around Expiry and Why It Is Not a Reliable Predictor
Synthetic Long and Short Explained: How Options Mimic Futures, Payoff, Margin, Costs and Why Traders Use Them
Diagonal Spread Explained: How Different Strikes and Different Expiries Are Combined, Payoff, Risks and How It Differs From a Calendar Spread
Iron Butterfly Explained: How the Four Leg Options Strategy Is Built, Maximum Profit and Loss, Break-Even Points and How It Differs From an Iron Condor
Ratio Spread Explained: How Buying One Option and Selling Two Works, Payoff, Unlimited Risk Side, Margin and When Traders Use It

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





